Life Technologies’ Prodigy System Secures CE Mark for In Vitro Diagnostic Use

HLA testing now available in Europe

CARLSBAD, Cailf. – April 26, 2010 – Life Technologies Corporation (NASDAQ: LIFE) today announced its Prodigy™ SSO HLA Typing Platform secured CE IVD clearance and can now be used for human leukocyte antigen (HLA) testing throughout the European Union.  When used in conjunction with other tests, HLA genotyping is one of the many factors clinicians use to assist in determining a potential solid organ donor-patient cross-match.  The approved system consists of the Prodigy instrument and A, B and DR locus-specific typing kits and software.

HLA markers are cell surface proteins that play a key role in regulating the immune system by acting as an alert mechanism when the body is invaded by foreign proteins.  This helps the immune system combat bacteria, parasites and viruses but can also cause the body to reject donated solid organs. 

The Prodigy platform is a push-button, automated system that uses microarray technology to detect and analyze HLA markers.  The automation enables clinical lab technicians to spend less time setting up their tests and more time analyzing results or preparing new samples.  Its automation and high throughput allows for improved efficiencies, higher reproducibility of data and the reduction or elimination of manual errors.

“We are committed to providing clinical laboratories and research facilities with an automated workflow solution for their HLA testing needs, and this approval is a significant milestone toward achieving that goal,” said Jim Janicki, Vice President and General Manager of Invitrogen Transplant Diagnostics for Life Technologies.  “Matching transplantation patients to solid organ donation is a critical step for patient survival and long term health.  The Prodigy Platform enables significant efficiencies and shorter turnaround times to improve on today’s current methods.”

About Life Technologies (

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact

Patty Zamora